

- I. Restrictive Pulmonary Disorders
 - a. Due to decreased lung expansion
 - b. Etiological classification
 - i. Parenchymal lung disorders: fibrotic interstitial lung disease, atelectatic disorders
 - ii. Pleural space disorders → between parietal/viseral
 - iii. Chest wall disorders: kyphoscoliosis, ankylosing spondylitis, flail chest, disorders of obesity → adding fat to chest wall increases pressure and decreases space to expand
 - iv. Neuromuscular disorders
 - v. Pulmonary infection/inflammation: pneumonia, severe acute respiratory syndrome, pulmonary tuberculosis
- II. Fibrotic Interstitial Lung Disease
 - a. Etiology = unknown
 - b. Alveolar wall infiltration by cells, fluid and connective tissue
 - c. Incidence: 5/100,000
 - d. Acute (allergies, minutes) subacute, chronic
 - e. Can progress to irreversible fibrosis if untreated
 - f. Pathogenesis
 - i. Immune reaction: initial injury to alveolar epithelium or capillary endothelium, interstitial and alveolar wall thickening, increased interstitial collagen bundles
 - ii. Inflammation: early and reversible, triggers cause inflammation and increased inflammatory cells (injury increases membrane permeability and fluid/debris movement into alveoli)
 - 1. Stretching capillary pores
 - 2. Mast cells, neutrophils, macrophages, eosinophils
 - iii. Fibrosis: fibroblastic proliferation and collagen deposition due to increased interstitial mesenchymal cells and fibroblasts, alveolar walls thicken with increased fibrous tissue → cracking at alveoli and destruction will eventually kill the patient
 - iv. Destruction: end stage disease, loss of alveolar walls
 - g. Clinical manifestations
 - i. Progressive dyspnea with exercise and desaturation
 - ii. Rapid, shallow breathing
 - iii. Irritating, dry cough
 - iv. Nail bed clubbing, bibasilar (both bases of lungs) end-expiratory crackles
 - v. Late cyanosis
 - vi. Anorexia, weight loss → no energy
 - vii. Inability to increase cardiac output with exercise
 - h. Diagnosis
 - i. Chest X-ray → honeycomb pattern
 - ii. Open lung biopsy → surgery, take out the ribs and take a piece of the lung

- iii. Transbronchial biopsy → tube goes down to pinch a piece of the lung
- iv. Bronchoalveolar lavage → spray fluid which picks up fibroblasts, immunelalveolar cells, debris and analyze under a microscope
- i. Treatment
 - i. Smoking cessation, avoid environmental exposure
 - ii. Anti-inflammatory and immunosuppressive agents
 - iii. Lung transplant
- j. Sarcoidosis
 - i. Etiology: idiopathic
 - ii. Systemic disorder → affects all tissues
 - 1. Acute: common in women 20-30 years old → autoimmune that doesn't involve Ab
 - 2. Chronic: 30-40 years old
 - iii. Trigger causes alveolar macrophage activation
 - iv. Pathogenesis
 - 1. Multiple, uniform, noncaseating epithelioid granulomas → spread all over and change function of tissues
 - a. Noncasesating = solid
 - 2. Multiorgan: lymph nodes and lung*, skin, eyes, spleen, liver, kidney, bone marrow
 - 3. Fibrotic, surrounded by large histiocytes
 - 4. Abnormal T-cell function
 - v. Clinical manifestations
 - 1. Malaise, fatigue, weight loss, fever → tired, weak muscles
 - 2. Insidious dyspnea, dry cough
 - 3. Erythema nodosum, macules/papules, hyperpigmentation, subcutaneous nodules → subcutaneous nodules, red rash
 - 4. Hepatosplenomegaly, lymphadenopathy
 - a. enlarged
 - vi. Diagnosis
 - 1. Blood tests
 - a. Higher BP from ACE
 - b. Leukopenia, increased eosinophils, anemia,
 - c. High ESR, increased Ca (5% cases), high liver enzymes
 - d. Anergy: decreased sensitivity to specific Ag like Candida and mumps (70% cases) → false
 - i. Anergy = w/out energy due to leukopenia
 - e. High angiotensin converting enzymes: active disease (40-80% cases)
 - 2. Bronchoalveolar lavage: monitor cell content, fluid has high lymphocytes and high CD4:CD8 cell ratio
 - 3. Transbronchial lung biopsy: noncaseating granulomas (definitive diagnosis)
 - 4. Chest X-ray: differentiates stages (start with this)

- vii. Treatment
 - 1. Corticosteroids and immunosuppressants
- III. Atelectatic Disorders
 - a. ARDS → secondary to something else
 - i. Acute/Adult Respiratory Distress Syndrome
 - 1. Associated with other pathophysiological processes
 - 2. 125 000-150 000 cases/year in U.S., 30-60% mortality
 - ii. Etiology
 - 1. Severe trauma, sepsis (>40% cases), shock
 - 2. Aspiration of gastric acid: >30% cases
 - iii. Pathogenesis
 - 1. Widespread pulmonary inflammation
 - a. Noncardiogenic pulmonary edema: leaky pulmonary capillaries
 - b. Atelectasia associated with lack of surfactant
 - c. Fibrosis: inflammatory protein deposition
 - 2. Severe hypoxemia due to intrapulmonary blood shunting
 - a. Perfusion of large number of alveoli that are poorly ventilated (low ventilation-perfusion areas) or not ventilated (areas of shunt)
 - 3. Decrease in lung compliance
 - a. Due to surfactant loss/inactivation with subsequent increased recoil pressure
 - b. Proteinaceous fluid fills alveoli and impairs ventilation
 - 4. Diffuse, fluffy alveolar infiltrates
 - iv. Clinical manifestations
 - 1. Early
 - a. Sudden, marked, respiratory distress
 - b. Mild tachycardia, dyspnea, low PaO₂
 - c. Shallow, rapid breathing
 - 2. Late
 - a. Tachycardia, tachypnea, hypotension
 - b. Marked restlessness, cyanosis
 - c. Crackles and ronchi on auscultation, use of accessory muscles, intercostal and sternal retractions
 - v. Diagnosis
 - 1. Hallmark: hypoxemia refractory to increased supplemental oxygen levels
 - 2. ABG: hypoxia, acidosis, hypercapnia (high carbon dioxide)
 - 3. Chest X-ray: progressive, normal to diffuse “whiteout”
 - 4. Open lung biopsy: atelectasis, hyaline membranes, cell debris, interstitial and alveolar edema
 - vi. Treatment
 - 1. Treat the sepsis first so the body has time to heal